Fast Five Quiz: Management of Mantle Cell Lymphoma

Elwyn C. Cabebe, MD; Ann S. LaCasce, MD, MMSc

January 26, 2023

Various regimens are available for induction therapy for MCL. Guidelines from the NCCN recommend that patients with stage II bulky or stage III-IV MCL who show a partial response to induction therapy be considered for second-line therapy to achieve a complete response.

ISRT with or without chemoimmunotherapy may be considered for patients with stage I or stage II nonbulky MCL.

For patients with stage II bulky or stage III-IV MCL who are not candidates for stem cell transplant, less aggressive therapy is recommended.

Treatment with a BTK inhibitor is not a recommended first-line option.

Learn more about additional MCL management considerations and recommendations.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Elwyn C. Cabebe, Ann S. LaCasce. Fast Five Quiz: Management of Mantle Cell Lymphoma - Medscape - Jan 26, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Fast Five Quiz: Management of Mantle Cell Lymphoma

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Elwyn C. Cabebe, MD

Ann S. LaCasce, MD, MMSc

Comments

Email This

Feedback